ProCE Banner Activity

ExpressPoints: Targeting BTK in CLL: Expert Guidance on Selecting Single-Agent and Combination Therapy

Slideset Download
Download this short summary slideset of key takeaway points from a live presentation on BTK inhibitors in the treatment of CLL.

Released: November 04, 2021

Expiration: November 03, 2022

No longer available for credit.

Share

Faculty

Seema Ali Bhat

Seema Ali Bhat, MD

Associate Professor
Division of Hematology
Department of Medicine
The Ohio State University
Columbus, Ohio

Talha Munir

Talha Munir, MBBS, MRCP, FRCPath

Consultant Haematologist
Department of Haematology
St Jamess Hospital
Leeds, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Seema Ali Bhat, MD

Associate Professor
Division of Hematology
Department of Medicine
The Ohio State University
Columbus, Ohio

Seema Bhat, MD, has disclosed that she has received funds for research support from Acerta, AstraZeneca, and TG Therapeutics, and consulting fees from Acerta, AstraZeneca, and BeiGene.

Talha Munir, MBBS, MRCP, FRCPath

Consultant Haematologist
Department of Haematology
St Jamess Hospital
Leeds, United Kingdom

Talha Munir, MBBS, MRCP, FRCPath, has disclosed that he has received consulting fees from Alexion, AstraZeneca, Janssen and Roche; and fees for non-CME/CE Services from Alexion, AbbVie, AstraZeneca, and Janssen.